Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 762398, 10 pages
http://dx.doi.org/10.1155/2008/762398
Review Article

A Novel Mechanism of PPAR 𝛾 Regulation of TGF 𝛽 1 : Implication in Cancer Biology

1Department of Pharmacology, Institute of Biomedical Science, College of Medicine, Hanyang University, Seoul 133-791, South Korea
2Department of Medicine, College of Medicine, Chung-Ang University, Seoul 156-756, South Korea
3Innovative Drug Research Center for Metabolic and Inflammatory Disease, College of Pharmacy, Seoul National University, Seoul 151-742, South Korea

Received 20 February 2008; Revised 28 April 2008; Accepted 9 June 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Chang Ho Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. Rahimi and E. B. Leof, “TGF-β signaling: a tale of two responses,” Journal of Cellular Biochemistry, vol. 102, no. 3, pp. 593–608, 2007. View at Publisher · View at Google Scholar
  2. E. Piek, C.-H. Heldin, and P. T. Dijke, “Specificity, diversity, and regulation in TGF-β superfamily signaling,” The FASEB Journal, vol. 13, no. 15, pp. 2105–2124, 1999. View at Google Scholar
  3. A. B. Roberts and M. B. Sporn, “Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues,” Molecular Reproduction and Development, vol. 32, no. 2, pp. 91–98, 1992. View at Publisher · View at Google Scholar
  4. M. H. Jarrar and A. Baranova, “PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling,” Journal of Cellular and Molecular Medicine, vol. 11, no. 1, pp. 71–87, 2007. View at Publisher · View at Google Scholar
  5. M. Fu, J. Zhang, X. Zhu et al., “Peroxisome proliferator-activated receptor ? inhibits transforming growth factor ß-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3,” Journal of Biological Chemistry, vol. 276, no. 49, pp. 45888–45894, 2001. View at Publisher · View at Google Scholar
  6. W. Wang, F. Liu, and N. Chen, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists attenuate the profibrotic response induced by TGF-β1 in renal interstitial fibroblasts,” Mediators of Inflammation, vol. 2007, Article ID 62641, 7 pages, 2007. View at Publisher · View at Google Scholar
  7. C. Zhao, W. Chen, L. Yang, L. Chen, S. A. Stimpson, and A. M. Diehl, “PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells,” Biochemical and Biophysical Research Communications, vol. 350, no. 2, pp. 385–391, 2006. View at Publisher · View at Google Scholar
  8. Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu, “Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 54–65, 2006. View at Publisher · View at Google Scholar
  9. S. Zhou, S. Lechpammer, J. S. Greenberger, and J. Glowacki, “Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-β/Smad3 signaling,” Journal of Biological Chemistry, vol. 280, no. 24, pp. 22688–22696, 2005. View at Publisher · View at Google Scholar
  10. X. Liang, T. Kanjanabuch, S.-L. Mao et al., “Plasminogen activator inhibitor-1 modulates adipocyte differentiation,” American Journal of Physiology, vol. 290, no. 1, pp. E103–E113, 2006. View at Publisher · View at Google Scholar
  11. S. Redondo, E. Ruiz, C. G. Santos-Gallego, E. Padilla, and T. Tejerina, “Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-γ, transforming growth factor-β1, and a Smad2-dependent mechanism,” Diabetes, vol. 54, no. 3, pp. 811–817, 2005. View at Publisher · View at Google Scholar
  12. B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda, “Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells,” Diabetes, vol. 53, no. 1, pp. 200–208, 2004. View at Publisher · View at Google Scholar
  13. J. Han, D. P. Hajjar, J. M. Tauras, J. Feng, A. M. Gotto Jr., and A. C. Nicholson, “Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 1241–1246, 2000. View at Publisher · View at Google Scholar
  14. S. Ahdjoudj, K. Kaabeche, X. Holy et al., “Transforming growth factor-ß inhibits CCAAT/enhancer-binding protein expression and PPAR? activity in unloaded bone marrow stromal cells,” Experimental Cell Research, vol. 303, no. 1, pp. 138–147, 2005. View at Publisher · View at Google Scholar
  15. S. Zheng and A. Chen, “Disruption of transforming growth factor-β signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-γ in rat hepatic stellate cells,” American Journal of Physiology, vol. 292, no. 1, pp. G113–G123, 2007. View at Publisher · View at Google Scholar
  16. S.-J. Kim, A. Glick, M. B. Sporn, and A. B. Roberts, “Characterization of the promoter region of the human transforming growth factor-β1 gene,” Journal of Biological Chemistry, vol. 264, no. 1, pp. 402–408, 1989. View at Google Scholar
  17. R. Öklü and R. Hesketh, “The latent transforming growth factor β binding protein (LTBP) family,” Biochemical Journal, vol. 352, part 3, pp. 601–610, 2000. View at Publisher · View at Google Scholar
  18. S. J. Lee, E. K. Yang, and S. G. Kim, “Peroxisome proliferator-activated receptor-γ and retinoic acid X receptor α represses the TGFβ1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation,” Molecular Pharmacology, vol. 70, no. 1, pp. 415–425, 2006. View at Publisher · View at Google Scholar
  19. C. Weigert, K. Brodbeck, A. Bierhaus, H. U. Häring, and E. D. Schleicher, “c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones,” Biochemical and Biophysical Research Communications, vol. 304, no. 2, pp. 301–307, 2003. View at Publisher · View at Google Scholar
  20. Y. Inagaki, T. Nemoto, A. Nakao et al., “Interaction between GC Box binding factors and Smad proteins modulates cell lineage-specific a2(I) collagen gene transcription,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16573–16579, 2001. View at Publisher · View at Google Scholar
  21. Y. Inagaki, M. Mamura, Y. Kanamaru et al., “Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells,” Journal of Cellular Physiology, vol. 187, no. 1, pp. 117–123, 2001. View at Publisher · View at Google Scholar
  22. J. Massagué and Y.-G. Chen, “Controlling TGF-β signaling,” Genes and Development, vol. 14, no. 6, pp. 627–644, 2000. View at Google Scholar
  23. E. Piek, W. J. Ju, J. Heyer et al., “Functional characterization of transforming growth factor ß signaling in Smad2- and Smad3-deficient fibroblasts,” Journal of Biological Chemistry, vol. 276, no. 23, pp. 19945–19953, 2001. View at Publisher · View at Google Scholar
  24. J. L. Wrana, “Regulation of Smad activity,” Cell, vol. 100, no. 2, pp. 189–192, 2000. View at Publisher · View at Google Scholar
  25. L. Vindevoghel, R. J. Lechleider, A. Kon et al., “SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor ß,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14769–14774, 1998. View at Publisher · View at Google Scholar
  26. X.-H. Feng, X. Lin, and R. Derynck, “Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15Ink4B transcription in response to TGF-β,” The EMBO Journal, vol. 19, no. 19, pp. 5178–5193, 2000. View at Publisher · View at Google Scholar
  27. S. Dennler, S. Itoh, D. Vivien, P. ten Dijke, S. Huet, and J.-M. Gauthier, “Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene,” The EMBO Journal, vol. 17, no. 11, pp. 3091–3100, 1998. View at Publisher · View at Google Scholar
  28. R. S. Frey and K. M. Mulder, “Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells,” Cancer Research, vol. 57, no. 4, pp. 628–633, 1997. View at Google Scholar
  29. H. Watanabe, M. P. de Caestecker, and Y. Yamada, “Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-β-induced aggrecan gene expression in chondrogenic ATDC5 cells,” Journal of Biological Chemistry, vol. 276, no. 17, pp. 14466–14473, 2001. View at Publisher · View at Google Scholar
  30. T. Hayashida, M. Decaestecker, and H. W. Schnaper, “Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells,” The FASEB Journal, vol. 17, no. 11, pp. 1576–1578, 2003. View at Google Scholar
  31. F. Furukawa, K. Matsuzaki, S. Mori et al., “p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts,” Hepatology, vol. 38, no. 4, pp. 879–889, 2003. View at Publisher · View at Google Scholar
  32. M. Uemura, E. S. Swenson, M. D. A. Gaça, F. J. Giordano, M. Reiss, and R. G. Wells, “Smad2 and Smad3 play different roles in rat hepatic stellate cell function and α-smooth muscle actin organization,” Molecular Biology of the Cell, vol. 16, no. 9, pp. 4214–4224, 2005. View at Publisher · View at Google Scholar
  33. X. Liu, W. Wang, H. Hu et al., “Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-ß1 in cultured rat hepatic stellate cells,” Pharmaceutical Research, vol. 23, no. 1, pp. 82–89, 2006. View at Publisher · View at Google Scholar
  34. K. W. Kang, Y. G. Kim, M. K. Cho et al., “Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation,” The FASEB Journal, vol. 16, no. 14, pp. 1988–1990, 2002. View at Google Scholar
  35. R. S. Muraoka-Cook, N. Dumont, and C. L. Arteaga, “Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression,” Clinical Cancer Research, vol. 11, no. 2, pp. 937s–943s, 2005. View at Google Scholar
  36. R. Derynck, R. J. Akhurst, and A. Balmain, “TGF-β signaling in tumor suppression and cancer progression,” Nature Genetics, vol. 29, no. 2, pp. 117–129, 2001. View at Publisher · View at Google Scholar
  37. M. J. Truty and R. Urrutia, “Basics of TGF-β and pancreatic cancer,” Pancreatology, vol. 7, no. 5-6, pp. 423–435, 2007. View at Publisher · View at Google Scholar
  38. G. J. Hannon and D. Beach, “p15INK4B is a potential effector of TGF-β-induced cell cycle arrest,” Nature, vol. 371, no. 6494, pp. 257–261, 1994. View at Publisher · View at Google Scholar
  39. M. B. Datto, Y. Li, J. F. Panus, D. J. Howe, Y. Xiong, and X.-F. Wang, “Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 12, pp. 5545–5549, 1995. View at Publisher · View at Google Scholar
  40. J. A. Pietenpol, J. T. Holt, R. W. Stein, and H. L. Moses, “Transforming growth factor β1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 10, pp. 3758–3762, 1990. View at Publisher · View at Google Scholar
  41. M. G. Alexandrow, M. Kawabata, M. Aakre, and H. L. Moses, “Overexpression of the c-myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor β1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3239–3243, 1995. View at Publisher · View at Google Scholar
  42. Y. Kang, C.-R. Chen, and J. Massagué, “A self-enabling TGFβ response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells,” Molecular Cell, vol. 11, no. 4, pp. 915–926, 2003. View at Publisher · View at Google Scholar
  43. P. M. Siegel and J. Massagué, “Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer,” Nature Reviews Cancer, vol. 3, no. 11, pp. 807–820, 2003. View at Publisher · View at Google Scholar
  44. S. G. Kim, H.-S. Jong, T.-Y. Kim et al., “Transforming growth factor-ß1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells,” Molecular Biology of the Cell, vol. 15, no. 2, pp. 420–434, 2004. View at Publisher · View at Google Scholar
  45. J. E. Chipuk, M. Bhat, A. Y. Hsing, J. Ma, and D. Danielpour, “Bcl-xL blocks transforming growth factor-β1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 26614–26621, 2001. View at Publisher · View at Google Scholar
  46. A. M. Arias, “Epithelial mesenchymal interactions in cancer and development,” Cell, vol. 105, no. 4, pp. 425–431, 2001. View at Publisher · View at Google Scholar
  47. J. P. Thiery, “Epithelial-mesenchymal transitions in tumour progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002. View at Publisher · View at Google Scholar
  48. H. Hugo, M. L. Ackland, T. Blick et al., “Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression,” Journal of Cellular Physiology, vol. 213, no. 2, pp. 374–383, 2007. View at Publisher · View at Google Scholar
  49. A. Gal, T. Sjöblom, L. Fedorova, S. Imreh, H. Beug, and A. Moustakas, “Sustained TGFβ exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis,” Oncogene, vol. 27, no. 9, pp. 1218–1230, 2008. View at Publisher · View at Google Scholar
  50. K. Pardali and A. Moustakas, “Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer,” Biochimica et Biophysica Acta, vol. 1775, no. 1, pp. 21–62, 2007. View at Publisher · View at Google Scholar
  51. D. Medici, E. D. Hay, and D. A. Goodenough, “Cooperation between snail and LEF-1 transcription factors is essential for TGF-β1-induced epithelial-mesenchymal transition,” Molecular Biology of the Cell, vol. 17, no. 4, pp. 1871–1879, 2006. View at Publisher · View at Google Scholar
  52. L. Van Aelst and M. Symons, “Role of Rho family GTPases in epithelial morphogenesis,” Genes and Development, vol. 16, no. 9, pp. 1032–1054, 2002. View at Publisher · View at Google Scholar
  53. M. A. Friese, J. Wischhusen, W. Wick et al., “RNA interference targeting transforming growth factor-ß enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo,” Cancer Research, vol. 64, no. 20, pp. 7596–7603, 2004. View at Publisher · View at Google Scholar
  54. R. Coras, A. Hölsken, S. Seufert et al., “The peroxisome proliferator-activated receptor-? agonist troglitazone inhibits transforming growth factor-ß-mediated glioma cell migration and brain invasion,” Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1745–1754, 2007. View at Publisher · View at Google Scholar
  55. S.-K. Leivonen, R. Ala-aho, K. Koli, R. Grénman, J. Peltonen, and V.-M. Kähäri, “Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells,” Oncogene, vol. 25, no. 18, pp. 2588–2600, 2006. View at Publisher · View at Google Scholar
  56. S.-K. Leivonen and V.-M. Kähäri, “Transforming growth factor-β signaling in cancer invasion and metastasis,” International Journal of Cancer, vol. 121, no. 10, pp. 2119–2124, 2007. View at Publisher · View at Google Scholar
  57. M. Deckers, M. van Dinther, J. Buijs et al., “The tumor suppressor Smad4 is required for transforming growth factor ß-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells,” Cancer Research, vol. 66, no. 4, pp. 2202–2209, 2006. View at Publisher · View at Google Scholar
  58. Y. Kang, W. He, S. Tulley et al., “Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13909–13914, 2005. View at Publisher · View at Google Scholar
  59. W. Wick, M. Platten, and M. Weller, “Glioma cell invasion: regulation of metalloproteinase activity by TGF-β,” Journal of Neuro-Oncology, vol. 53, no. 2, pp. 177–185, 2001. View at Publisher · View at Google Scholar
  60. H. K. Rooprai, G. J. Rucklidge, C. Panou, and G. J. Pilkington, “The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells,” British Journal of Cancer, vol. 82, no. 1, pp. 52–55, 2000. View at Publisher · View at Google Scholar
  61. N. Johansson, R. Ala-aho, V. Uitto et al., “Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase,” Journal of Cell Science, vol. 113, no. 2, pp. 227–235, 2000. View at Google Scholar
  62. S.-W. Lin, M.-T. Lee, F.-C. Ke et al., “TGF ß1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103,” Clinical & Experimental Metastasis, vol. 18, no. 6, pp. 493–499, 2000. View at Publisher · View at Google Scholar
  63. K. Giehl, Y. Imamichi, and A. Menke, “Smad4-independent TGF-β signaling in tumor cell migration,” Cells Tissues Organs, vol. 185, no. 1–3, pp. 123–130, 2007. View at Publisher · View at Google Scholar
  64. M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and R. A. Flavell, “Transforming growth factor-β regulation of immune responses,” Annual Review of Immunology, vol. 24, pp. 99–146, 2006. View at Publisher · View at Google Scholar
  65. J. H. Kehrl, L. M. Wakefield, A. B. Roberts et al., “Production of transforming growth factor ß by human T lymphocytes and its potential role in the regulation of T cell growth,” Journal of Experimental Medicine, vol. 163, no. 5, pp. 1037–1050, 1986. View at Publisher · View at Google Scholar
  66. A. Ma, R. Koka, and P. Burkett, “Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis,” Annual Review of Immunology, vol. 24, pp. 657–679, 2006. View at Publisher · View at Google Scholar
  67. S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, “Transforming growth factor-β and the immune response: implications for anticancer therapy,” Clinical Cancer Research, vol. 13, no. 18, pp. 5262–5270, 2007. View at Publisher · View at Google Scholar
  68. M. Ahmadzadeh and S. A. Rosenberg, “TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells,” Journal of Immunology, vol. 174, no. 9, pp. 5215–5223, 2005. View at Google Scholar
  69. A. H. Rook, J. H. Kehrl, L. M. Wakefield et al., “Effects of transforming growth factor ß on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness,” Journal of Immunology, vol. 136, no. 10, pp. 3916–3920, 1986. View at Google Scholar
  70. G. Bellone, M. Aste-Amezaga, G. Trinchieri, and U. Rodeck, “Regulation of NK cell functions by TGF-β1,” Journal of Immunology, vol. 155, no. 3, pp. 1066–1073, 1995. View at Google Scholar
  71. F. Geissmann, P. Revy, A. Regnault et al., “TGF-ß1 prevents the noncognate maturation of human dendritic Langerhans cells,” Journal of Immunology, vol. 162, no. 8, pp. 4567–4575, 1999. View at Google Scholar
  72. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar
  73. G. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPAR?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002. View at Publisher · View at Google Scholar
  74. T. Ikezoe, C. W. Miller, S. Kawano et al., “Mutational analysis of the peroxisome proliferator-activated receptor ? in human malignancies,” Cancer Research, vol. 61, no. 13, pp. 5307–5310, 2001. View at Google Scholar
  75. P. Sarraf, E. Mueller, W. M. Smith et al., “Loss-of-function mutations in PPAR? associated with human colon cancer,” Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999. View at Publisher · View at Google Scholar
  76. T. Kubota, K. Koshizuka, E. A. Williamson et al., “Ligand for peroxisome proliferator-activated receptor ? (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,” Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998. View at Google Scholar
  77. G. G. Chen, J. F. Lee, S. H. Wang, U. P. F. Chan, P. C. Ip, and W. Y. Lau, “Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and Nf-κB in human colon cancer,” Life Sciences, vol. 70, no. 22, pp. 2631–2646, 2002. View at Publisher · View at Google Scholar
  78. J. A. Brockman, R. A. Gupta, and R. N. Dubois, “Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells,” Gastroenterology, vol. 115, no. 5, pp. 1049–1055, 1998. View at Publisher · View at Google Scholar
  79. M. Kato, T. Kusumi, S. Tsuchida, M. Tanaka, M. Sasaki, and H. Kudo, “Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 2, pp. 73–79, 2004. View at Publisher · View at Google Scholar
  80. K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, “Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2170–2177, 2001. View at Publisher · View at Google Scholar
  81. P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through PPAR?,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998. View at Publisher · View at Google Scholar
  82. J. Yu, L. Qiao, L. Zimmermann et al., “Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo,” Hepatology, vol. 43, no. 1, pp. 134–143, 2006. View at Publisher · View at Google Scholar
  83. A. P. Heaney, M. Fernando, and S. Melmed, “PPAR-γ receptor ligands: novel therapy for pituitary adenomas,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1381–1388, 2003. View at Publisher · View at Google Scholar
  84. C. Day, “Thiazolidinediones: a new class of antidiabetic drugs,” Diabetic Medicine, vol. 16, no. 3, pp. 179–192, 1999. View at Publisher · View at Google Scholar
  85. J.-R. Weng, C.-Y. Chen, J. J. Pinzone, M. D. Ringel, and C.-S. Chen, “Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 401–413, 2006. View at Publisher · View at Google Scholar
  86. S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,” Cancer Research, vol. 61, no. 16, pp. 6213–6218, 2001. View at Google Scholar
  87. M.-A. Bae and B. J. Song, “Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells,” Molecular Pharmacology, vol. 63, no. 2, pp. 401–408, 2003. View at Publisher · View at Google Scholar
  88. S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling, “Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ: a novel mechanism for its anti-tumorigenic activity,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 5845–5853, 2003. View at Publisher · View at Google Scholar
  89. A. Sugimura, Y. Kiriyama, H. Nochi et al., “Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor,” Biochemical and Biophysical Research Communications, vol. 261, no. 3, pp. 833–837, 1999. View at Publisher · View at Google Scholar
  90. A.-M. Lefebvre, I. Chen, P. Desreumaux et al., “Activation of the peroxisome proliferator-activated receptor ? promotes the development of colon tumors in C57BL/6J-APCMin/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998. View at Publisher · View at Google Scholar
  91. E. Saez, J. Rosenfeld, A. Livolsi et al., “PPAR? signaling exacerbates mammary gland tumor development,” Genes and Development, vol. 18, no. 5, pp. 528–540, 2004. View at Publisher · View at Google Scholar
  92. E. Y. Park, I. J. Cho, and S. G. Kim, “Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-γ and retinoid X receptor heterodimer,” Cancer Research, vol. 64, no. 10, pp. 3701–3713, 2004. View at Publisher · View at Google Scholar
  93. F.-S. Chou, P.-S. Wang, S. Kulp, and J. J. Pinzone, “Effects of thiazolidinediones on differentiation, proliferation, and apoptosis,” Molecular Cancer Research, vol. 5, no. 6, pp. 523–530, 2007. View at Publisher · View at Google Scholar
  94. E. A. Thompson, “PPARγ physiology and pathology in gastrointestinal epithelial cells,” Molecules and Cells, vol. 24, no. 2, pp. 167–176, 2007. View at Google Scholar
  95. Y. Kodera, K. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato, “Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33201–33204, 2000. View at Publisher · View at Google Scholar
  96. K. W. Kang, I. J. Cho, C. H. Lee, and S. G. Kim, “Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein β activation in the induction of glutathione S-transferase by oltipraz,” Journal of the National Cancer Institute, vol. 95, no. 1, pp. 53–66, 2003. View at Google Scholar
  97. K. W. Kang, E. Y. Park, and S. G. Kim, “Activation of CCAAT/enhancer-binding protein β by 2-amino-3-methoxyflavone (PD98059) leads to the induction of glutathione S-transferase A2,” Carcinogenesis, vol. 24, no. 3, pp. 475–482, 2003. View at Publisher · View at Google Scholar
  98. S. M. A. Holmbeck, H. J. Dyson, and P. E. Wright, “DNA-induced conformational changes are the basis for cooperative dimerization by the DNA binding domain of the retinoid X receptor,” Journal of Molecular Biology, vol. 284, no. 3, pp. 533–539, 1998. View at Publisher · View at Google Scholar
  99. P. Jenö, L. M. Ballou, I. Novak-Hofer, and G. Thomas, “Identification and characterization of a mitogen-activated S6 kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 2, pp. 406–410, 1988. View at Publisher · View at Google Scholar
  100. R. P. de Groot, L. M. Ballou, and P. Sassone-Corsi, “Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression,” Cell, vol. 79, no. 1, pp. 81–91, 1994. View at Publisher · View at Google Scholar
  101. H. Harada, J. S. Andersen, M. Mann, N. Terada, and S. J. Korsmeyer, “p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9666–9670, 2001. View at Publisher · View at Google Scholar
  102. X. Wang, W. Li, M. Williams, N. Terada, D. R. Alessi, and C. G. Proud, “Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase,” The EMBO Journal, vol. 20, no. 16, pp. 4370–4379, 2001. View at Publisher · View at Google Scholar
  103. J. Zhu, J. Wu, E. Frizell et al., “Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis,” Gastroenterology, vol. 117, no. 5, pp. 1198–1204, 1999. View at Publisher · View at Google Scholar
  104. E. Biecker, A. De Gottardi, M. Neef et al., “Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms,” Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 3, pp. 952–961, 2005. View at Publisher · View at Google Scholar
  105. D. M. Sabatini, H. Erdjument-Bromage, M. Lui, P. Tempst, and S. H. Snyder, “RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs,” Cell, vol. 78, no. 1, pp. 35–43, 1994. View at Publisher · View at Google Scholar
  106. K. S. Lee, S. J. Park, P. H. Hwang et al., “PPAR-gamma modulates allergic inflammation through up-regulation of PTEN,” The FASEB Journal, vol. 19, no. 8, pp. 1033–1035, 2005. View at Publisher · View at Google Scholar
  107. J.-L. Liu, X. Sheng, Z. K. Hortobagyi, Z. Mao, G. E. Gallick, and W. K. A. Yung, “Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation,” Molecular and Cellular Biology, vol. 25, no. 14, pp. 6211–6224, 2005. View at Publisher · View at Google Scholar
  108. C. Weigert, K. Brodbeck, A. Bierhaus, H. U. Häring, and E. D. Schleicher, “c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones,” Biochemical and Biophysical Research Communications, vol. 304, no. 2, pp. 301–307, 2003. View at Publisher · View at Google Scholar
  109. G. Salbert, A. Fanjul, F. J. Piedrafita et al., “Retinoic acid receptors and retinoid X receptor-a down-regulate the transforming growth factor-ß1 promoter by antagonizing AP-1 activity,” Molecular Endocrinology, vol. 7, no. 10, pp. 1347–1356, 1993. View at Publisher · View at Google Scholar
  110. G. Narla, K. E. Heath, H. L. Reeves et al., “KLF6, a candidate tumor suppressor gene mutated in prostate cancer,” Science, vol. 294, no. 5551, pp. 2563–2566, 2001. View at Publisher · View at Google Scholar
  111. D. A. Slavin, N. P. Koritschoner, C. C. Prieto, F. J. López-Díaz, B. Chatton, and J. L. Bocco, “A new role for the Krüppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function,” Oncogene, vol. 23, no. 50, pp. 8196–8205, 2004. View at Publisher · View at Google Scholar
  112. V. Ratziu, A. Lalazar, L. Wong et al., “Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9500–9505, 1998. View at Publisher · View at Google Scholar
  113. Y. Kim, V. Ratziu, S.-G. Choi et al., “Transcriptional activation of transforming growth factor ß1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1: potential mechanisms for autocrine fibrogenesis in response to injury,” Journal of Biological Chemistry, vol. 273, no. 50, pp. 33750–33758, 1998. View at Publisher · View at Google Scholar
  114. V. G. Warke, M. P. Nambiar, S. Krishnan et al., “Transcriptional activation of the human inducible nitric-oxide synthase promoter by Krüppel-like factor 6,” Journal of Biological Chemistry, vol. 278, no. 17, pp. 14812–14819, 2003. View at Publisher · View at Google Scholar
  115. L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith, and C. H. Macphee, “Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN,” Current Biology, vol. 11, no. 10, pp. 764–768, 2001. View at Publisher · View at Google Scholar